Merck & Co. (MRK)
(Real Time Quote from BATS)
$130.14 USD
-1.06 (-0.81%)
Updated Apr 29, 2024 02:10 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MRK 130.14 -1.06(-0.81%)
Will MRK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MRK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRK
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
MRK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Other News for MRK
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Merck late-stage data strengthens profile of pneumonia vaccine candidate
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
Novo Nordisk: Growth Is Still A Better Choice
TECB: Not A Good Choice When Compared To Other Traditional Technology ETFs